1. Home
  2. MAX vs MLYS Comparison

MAX vs MLYS Comparison

Compare MAX & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MediaAlpha Inc.

MAX

MediaAlpha Inc.

HOLD

Current Price

$12.88

Market Cap

722.8M

Sector

Industrials

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$37.91

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MAX
MLYS
Founded
2014
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
722.8M
3.1B
IPO Year
2020
2023

Fundamental Metrics

Financial Performance
Metric
MAX
MLYS
Price
$12.88
$37.91
Analyst Decision
Buy
Strong Buy
Analyst Count
6
7
Target Price
$17.00
$47.33
AVG Volume (30 Days)
483.3K
1.6M
Earning Date
10-29-2025
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,123,093,000.00
N/A
Revenue This Year
$30.80
N/A
Revenue Next Year
$9.28
N/A
P/E Ratio
N/A
N/A
Revenue Growth
64.86
N/A
52 Week Low
$7.33
$8.24
52 Week High
$13.92
$47.65

Technical Indicators

Market Signals
Indicator
MAX
MLYS
Relative Strength Index (RSI) 51.25 43.48
Support Level $12.60 $36.01
Resistance Level $13.21 $39.15
Average True Range (ATR) 0.52 1.81
MACD -0.07 -0.16
Stochastic Oscillator 28.15 31.53

Price Performance

Historical Comparison
MAX
MLYS

About MAX MediaAlpha Inc.

MediaAlpha Inc provides a platform that facilitates insurance carriers and distributors target and acquire customers. The company's technology platform brings insurance carriers and consumers together through a real-time, transparent, and results-driven ecosystem. It acts as a customer acquisition channel in the areas of property & casualty insurance, health insurance, and life insurance. It operates in the United States and generates revenue by earning a fee for each consumer referral sold on its platform.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: